Sector
PharmaceuticalsOpen
₹50.82Prev. Close
₹49.52Turnover(Lac.)
₹5,327.12Day's High
₹52.9Day's Low
₹50.2252 Week's High
₹100.952 Week's Low
₹42.05Book Value
₹21.51Face Value
₹2Mkt Cap (₹ Cr.)
2,848.81P/E
20.89EPS
2.37Divi. Yield
017 Jan 2025
12:00 AM
EGM
11 Sep 2024
12:00 AM
AGM
Announcement Date: 11 Sep, 2024
11 Sep 2024
12:00 AM
BookCloser
3 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.
Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.
Here are some of the stocks that may see significant price movement today: Tata Motors, ITC, Kalyan Jewellers, etc.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 102.23 | 102.23 | 121.81 | 133.71 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 786.8 | 677.89 | 476.36 | 311.26 |
Net Worth | 889.03 | 780.12 | 598.17 | 444.97 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,112.42 | 791.98 | 560.83 | 547.5 |
yoy growth (%) | 40.45 | 41.21 | 2.43 | 21 |
Raw materials | -736.61 | -521.08 | -342.59 | -335.73 |
As % of sales | 66.21 | 65.79 | 61.08 | 61.32 |
Employee costs | -123.2 | -98.07 | -68.21 | -60.79 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 94.24 | 37.48 | 26.11 | 23.16 |
Depreciation | -28.11 | -34.43 | -33.39 | -33.56 |
Tax paid | 0 | -5.14 | 0 | 0 |
Working capital | -26.96 | 124.59 | -1.66 | 17.45 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 40.45 | 41.21 | 2.43 | 21 |
Op profit growth | 74.31 | 6.96 | -0.35 | -5.78 |
EBIT growth | 143.44 | 29.72 | -0.75 | 0.61 |
Net profit growth | 191.49 | 23.8 | 12.72 | 46.83 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 | 853.07 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 | 853.07 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 13.97 | 6.13 | 10.31 | 12.07 | 9.48 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,713.65 | 130.56 | 4,11,306 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,666 | 72.52 | 1,50,342.82 | 594 | 0.53 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,452.35 | 25.21 | 1,17,322.54 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,207.1 | 59.54 | 1,08,614.11 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,421.9 | 51.66 | 99,891.45 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sushil Suri
Company Sec. & Compli. Officer
Vipul Kumar Srivatava
Whole-time Director
Sanjay Suri
Non-Exec. & Independent Dir.
Praveen Kumar Dutt
Non-Exec. & Independent Dir.
Savita
Independent Director
Sharad Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Morepen Laboratories Ltd
Summary
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing locatio
Read More
What is the Morepen Laboratories Ltd share price today?
The Morepen Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹51.99 today.
What is the Market Cap of Morepen Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Morepen Laboratories Ltd is ₹2848.81 Cr. as of 03 Apr ‘25
What is the PE and PB ratio of Morepen Laboratories Ltd?
The PE and PB ratios of Morepen Laboratories Ltd is 20.89 and 2.36 as of 03 Apr ‘25
What is the 52 Week High and Low of Morepen Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Morepen Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Morepen Laboratories Ltd is ₹42.05 and ₹100.9 as of 03 Apr ‘25
What is the CAGR of Morepen Laboratories Ltd?
Morepen Laboratories Ltd's CAGR for 5 Years at 35.23%, 3 Years at 4.10%, 1 Year at 4.92%, 6 Month at -41.60%, 3 Month at -37.24% and 1 Month at 10.41%.
What is the shareholding pattern of Morepen Laboratories Ltd?
The shareholding pattern of Morepen Laboratories Ltd is as follows:
Promoters - 35.65 %
Institutions - 3.87 %
Public - 60.47 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
